Feasibility study of FOLFIRINOX as first-line chemotherapy for metastatic pancreatic cancer (KOBE FOLFIRINOX study)

被引：0
|
作者：
Hatachi, Yukimasa [1 ]
Satake, Hironaga [1 ]
Kotake, Takeshi [1 ]
Ogata, Takatsugu [1 ]
Okita, Yoshihiro [2 ]
Yasui, Hisateru [1 ]
Tsuji, Akihito [2 ]
机构：
[1] Kobe City Med Ctr Gen Hosp, Dept Med Oncol, Kobe, Hyogo, Japan
[2] Kagawa Univ Hosp, Dept Clin Oncol, Miki, Kagawa, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-104
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II study of modified FOLFIRINOX for chemotherapy-naive patients with metastatic pancreatic cancer
    Ueno, Makoto
    Ozaka, Masato
    Ishii, Hiroshi
    Sato, Tosiya
    Ikeda, Masafumi
    Uesugi, Kazuhiro
    Sata, Naohiro
    Miyashita, Kouichirou
    Mizuno, Nobumasa
    Tsuji, Kunihiro
    Okusaka, Takuji
    Furuse, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study
    Adenis, Antoine
    Ghiringhelli, Francois
    Gauthier, Ludovic
    Mazard, Thibault
    Evesque, Ludovic
    Evrard, Alexandre
    Chalbos, Patrick
    Moussion, Aurore
    Gourgou, Sophie
    Ychou, Marc
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (03) : 443 - 452
  • [33] FOLFIRINOX as a first-line chemotherapy for patients (pts) with advanced biliary tract cancer (BTC)
    Ulusakarya, A.
    Karray, W.
    Abdou, J.
    Karaboue, A.
    Haydar, M.
    Krimi, S.
    Gumus, Y.
    Almohamad, W.
    Goldschmidt, E.
    Biondani, P.
    Morere, J. F.
    ANNALS OF ONCOLOGY, 2018, 29 : 260 - 260
  • [34] SECOND-LINE CHEMOTHERAPY BY FOLFIRINOX WITH UNRESECTABLE PANCREATIC CANCER (PHASE I, II STUDY)
    Kobayashi, N.
    Shimamura, T.
    Tokuhisa, M.
    Goto, A.
    Endo, I.
    Ichikawa, Y.
    ANNALS OF ONCOLOGY, 2013, 24
  • [35] Second-line chemotherapy by FOLFIRINOX with unresectable pancreatic cancer (phase I, II study)
    Kobayashi, Noritoshi
    Tokuhisa, Motohiko
    Goto, Ayumu
    Endo, Itaru
    Ichikawa, Yasushi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [36] FOLFIRINOX as first-line therapy in patients with metastatic gastroesophageal cancers (GEC).
    Lockhart, Albert C.
    Krajewski, Kenneth Anthony
    Wang-Gillam, Andrea
    Amin, Manik
    Sorscher, Steven
    Lim, Kian-Huat
    Tan, Benjamin R.
    Picus, Joel
    Hecky, Anne
    Allen, Kenisha
    Peterson, Jaclyn D.
    O'Day, Emily
    Marsh, Robert de Wilton
    Kozloff, Mark
    Polite, Blase N.
    Kindler, Hedy Lee
    Sharma, Manish
    Catenacci, Daniel Virgil Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [37] Prognostic Significance of Disease Control at 12 Weeks in Patients With Advanced Pancreatic Cancer Receiving FOLFIRINOX as First-line Chemotherapy
    Batra, Atul
    Tang, Patricia A.
    Cheung, Winson Y.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (10): : 519 - 525
  • [38] Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel
    Riedl, Jakob M.
    Schwarzenbacher, Esther
    Moik, Florian
    Horvath, Lena
    Gantschnigg, Antonia
    Renneberg, Felix
    Posch, Florian
    Barth, Dominik A.
    Stotz, Michael
    Pichler, Martin
    Hatzl, Stefan
    Fandler-Hofler, Simon
    Gressenberger, Paul
    Gary, Thomas
    Jost, Philipp J.
    Greil, Richard
    Ay, Cihan
    Djanani, Angela
    Gerger, Armin
    Schlick, Konstantin
    THROMBOSIS AND HAEMOSTASIS, 2022, 122 (04) : 633 - 645
  • [39] A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer
    Masato Ozaka
    Hiroshi Ishii
    Tosiya Sato
    Makoto Ueno
    Masafumi Ikeda
    Kazuhiro Uesugi
    Naohiro Sata
    Kouichirou Miyashita
    Nobumasa Mizuno
    Kunihiro Tsuji
    Takuji Okusaka
    Junji Furuse
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 1017 - 1023
  • [40] Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study
    Lu Zou
    Xuechuan Li
    Xiangsong Wu
    Jiujie Cui
    Xuya Cui
    Xiaoling Song
    Tai Ren
    Xusheng Han
    Yidi Zhu
    Huaifeng Li
    Wenguang Wu
    Xu’an Wang
    Wei Gong
    Liwei Wang
    Maolan Li
    Wan Yee Lau
    Yingbin Liu
    BMC Cancer, 21
12345